This paper Described validated high performance liquid chromatographic (HPTLC) method for estimation of Rosuvastatin Calcium (ROS) and Ezetimibe (EZE) in tablet dosage form. The method involved separation of components by TLC on a precoated silica gel 60 F254 using a mixture of n-butanol: methanol (3:1) as a mobile phase. Detection of spots was carried out at 274 nm and 230 nm for Rosuvastatin Calcium and Ezetimibe combinations, respectively. The mean retardation factor for Rosuvastatin Calcium and Ezetimibe were found to be 0.90 ±0.01, 0.82±0.05, respectively. The linearity and range was 0.1 to 0.5 μg/spot for two drugs. The method was validated for precision, accuracy and reproducibility
